GLP-1 (9-36) amide: Precision GLP-1 Receptor Antagonist for Metabolic Regulation Studies

Executive Summary: GLP-1 (9-36) amide is a validated peptide antagonist for the human GLP-1 receptor, enabling precise interrogation of GLP-1 receptor signaling in metabolic and diabetes research (Chepurny et al., 2019). The peptide is supplied by APExBIO (SKU B5404) with confirmed 100% purity (HPLC, MS), and a molecular weight of 3089.44 Da (APExBIO product page). It is insoluble in DMSO, ethanol, and water, requiring specialized handling and storage at -20°C. Utilization of GLP-1 (9-36) amide facilitates reproducible delineation of incretin hormone signaling pathways and metabolic regulatory networks (PeptideBridge 2022). The product is essential for studies requiring selective inhibition of GLP-1 receptor-mediated responses in vitro and in vivo.

Biological Rationale

The glucagon-like peptide-1 (GLP-1) receptor is a class B G protein-coupled receptor central to incretin hormone signaling and insulin secretion modulation (Chepurny et al., 2019). GLP-1 is secreted by enteroendocrine L-cells and acts on pancreatic β-cells to potentiate glucose-dependent insulin release. Dysregulation of GLP-1 receptor signaling is implicated in type 2 diabetes mellitus (T2D) pathophysiology. The development of specific antagonists, such as GLP-1 (9-36) amide, enables the selective inhibition of GLP-1 receptor pathways—critical for dissecting receptor-specific metabolic effects and understanding the complexity of GPCR promiscuity (PeptideBridge review).

Mechanism of Action of GLP-1 (9-36) amide

GLP-1 (9-36) amide is a truncated peptide derived from the native GLP-1 sequence. It functions as a competitive antagonist at the human GLP-1 receptor (GLP-1R), preventing endogenous GLP-1 or agonist peptides from activating downstream cAMP signaling. The inhibition is achieved via high-affinity binding to the orthosteric site of GLP-1R, blocking receptor activation and subsequent insulinotropic effects (Chepurny et al., 2019). This selective antagonism allows researchers to isolate GLP-1R-specific contributions in metabolic regulation and incretin studies.

Evidence & Benchmarks

• GLP-1 (9-36) amide robustly inhibits GLP-1-induced cAMP accumulation in INS-1 832/13 cells, confirming antagonism at the GLP-1 receptor (Chepurny et al., 2019).
• Peptide purity is validated to 100% by HPLC and mass spectrometry under standard storage at -20°C in desiccated conditions (APExBIO).
• GLP-1 (9-36) amide does not significantly inhibit glucagon or GIP receptor activity at concentrations effective for GLP-1R blockade, supporting specificity (Chepurny et al., 2019).
• In FRET-based cAMP assays, GLP-1 (9-36) amide consistently distinguishes GLP-1R-mediated from off-target GPCR responses (Chepurny et al., 2019).
• Solubility profile: insoluble in DMSO, ethanol, and water; requires specialized handling for dissolution and prompt use after preparation (APExBIO).

This article clarifies and extends the operational benchmarks discussed in the PrecisionFDA advanced antagonist review by providing updated evidence for specificity and workflow integration.

Applications, Limits & Misconceptions

GLP-1 (9-36) amide is utilized in:

• GLP-1 receptor signaling research to map receptor-specific metabolic pathways.
• Preclinical models of type 2 diabetes for dissecting the role of incretin hormones.
• High-throughput cAMP and FRET assays for receptor pathway deconvolution (Chepurny et al., 2019).
• Studies requiring temporal control of GLP-1R antagonism due to its instability in solution and rapid onset of action.

Compared to the foundational overview in PeptideBridge's precision antagonist article, this article further delineates the product's limits regarding off-target effects and solubility constraints.

Common Pitfalls or Misconceptions

• GLP-1 (9-36) amide is not a pan-GPCR antagonist; it lacks significant activity at glucagon or GIP receptors at standard concentrations (Chepurny et al., 2019).
• Improper dissolution (attempting to solubilize in DMSO, ethanol, or water) leads to precipitation and loss of activity (APExBIO).
• Long-term storage in solution degrades peptide integrity; only short-term usage post-preparation is recommended.
• Not suitable as a therapeutic; intended strictly for research applications.
• Do not assume cross-reactivity with rodent GLP-1R unless directly validated.

Workflow Integration & Parameters

GLP-1 (9-36) amide (APExBIO B5404) is supplied as a white lyophilized solid. The molecular weight is 3089.44 Da; the chemical formula is C140H214N36O43. Store desiccated at -20°C. For experimental use, reconstitute with specialized buffers immediately before use; avoid DMSO, ethanol, and water due to insolubility. Shipping is on blue ice (small molecules) or dry ice (modified nucleotides). Confirm purity with the included Certificate of Analysis. For best results, use within one hour of dissolution. For detailed operational benchmarks and a comparison of antagonist profiles, see this article—where this dossier provides updated solubility and workflow data.

Conclusion & Outlook

GLP-1 (9-36) amide is a gold-standard GLP-1 receptor antagonist peptide, enabling reproducible, high-specificity research in GLP-1 receptor signaling and metabolic regulation. Its validated specificity, defined handling, and benchmarked purity make it indispensable for type 2 diabetes and incretin pathway studies. The product's role in precise dissection of receptor-mediated responses is supported by robust evidence and operational clarity (Chepurny et al., 2019). For additional details or ordering, consult the GLP-1 (9-36) amide product page at APExBIO.